In:
PLOS Pathogens, Public Library of Science (PLoS), Vol. 19, No. 5 ( 2023-5-31), p. e1011359-
Abstract:
The modestly efficacious HIV-1 vaccine regimen (RV144) conferred 31% vaccine efficacy at 3 years following the four-shot immunization series, coupled with rapid waning of putative immune correlates of decreased infection risk. New strategies to increase magnitude and durability of protective immunity are critically needed. The RV305 HIV-1 clinical trial evaluated the immunological impact of a follow-up boost of HIV-1-uninfected RV144 recipients after 6–8 years with RV144 immunogens (ALVAC-HIV alone, AIDSVAX B/E gp120 alone, or ALVAC-HIV + AIDSVAX B/E gp120). Previous reports demonstrated that this regimen elicited higher binding, antibody Fc function, and cellular responses than the primary RV144 regimen. However, the impact of the canarypox viral vector in driving antibody specificity, breadth, durability and function is unknown. We performed a follow-up analysis of humoral responses elicited in RV305 to determine the impact of the different booster immunogens on HIV-1 epitope specificity, antibody subclass, isotype, and Fc effector functions. Importantly, we observed that the ALVAC vaccine component directly contributed to improved breadth, function, and durability of vaccine-elicited antibody responses. Extended boosts in RV305 increased circulating antibody concentration and coverage of heterologous HIV-1 strains by V1V2-specific antibodies above estimated protective levels observed in RV144. Antibody Fc effector functions, specifically antibody-dependent cellular cytotoxicity and phagocytosis, were boosted to higher levels than was achieved in RV144. V1V2 Env IgG3, a correlate of lower HIV-1 risk, was not increased; plasma Env IgA (specifically IgA1), a correlate of increased HIV-1 risk, was elevated. The quality of the circulating polyclonal antibody response changed with each booster immunization. Remarkably, the ALVAC-HIV booster immunogen induced antibody responses post-second boost, indicating that the viral vector immunogen can be utilized to selectively enhance immune correlates of decreased HIV-1 risk. These results reveal a complex dynamic of HIV-1 immunity post-vaccination that may require careful balancing to achieve protective immunity in the vaccinated population. Trial registration : RV305 clinical trial (ClinicalTrials.gov number, NCT01435135 ). ClinicalTrials.gov Identifier: NCT00223080 .
Type of Medium:
Online Resource
ISSN:
1553-7374
DOI:
10.1371/journal.ppat.1011359
DOI:
10.1371/journal.ppat.1011359.g001
DOI:
10.1371/journal.ppat.1011359.g002
DOI:
10.1371/journal.ppat.1011359.g003
DOI:
10.1371/journal.ppat.1011359.g004
DOI:
10.1371/journal.ppat.1011359.g005
DOI:
10.1371/journal.ppat.1011359.g006
DOI:
10.1371/journal.ppat.1011359.g007
DOI:
10.1371/journal.ppat.1011359.g008
DOI:
10.1371/journal.ppat.1011359.g009
DOI:
10.1371/journal.ppat.1011359.g010
DOI:
10.1371/journal.ppat.1011359.t001
DOI:
10.1371/journal.ppat.1011359.t002
DOI:
10.1371/journal.ppat.1011359.t003
DOI:
10.1371/journal.ppat.1011359.t004
DOI:
10.1371/journal.ppat.1011359.t005
DOI:
10.1371/journal.ppat.1011359.t006
DOI:
10.1371/journal.ppat.1011359.t007
DOI:
10.1371/journal.ppat.1011359.t008
DOI:
10.1371/journal.ppat.1011359.s001
DOI:
10.1371/journal.ppat.1011359.s002
DOI:
10.1371/journal.ppat.1011359.s003
DOI:
10.1371/journal.ppat.1011359.s004
DOI:
10.1371/journal.ppat.1011359.s005
DOI:
10.1371/journal.ppat.1011359.s006
DOI:
10.1371/journal.ppat.1011359.s007
DOI:
10.1371/journal.ppat.1011359.s008
DOI:
10.1371/journal.ppat.1011359.s009
DOI:
10.1371/journal.ppat.1011359.s010
DOI:
10.1371/journal.ppat.1011359.s011
DOI:
10.1371/journal.ppat.1011359.s012
DOI:
10.1371/journal.ppat.1011359.s013
DOI:
10.1371/journal.ppat.1011359.s014
DOI:
10.1371/journal.ppat.1011359.s015
DOI:
10.1371/journal.ppat.1011359.s016
DOI:
10.1371/journal.ppat.1011359.s017
DOI:
10.1371/journal.ppat.1011359.s018
DOI:
10.1371/journal.ppat.1011359.s019
DOI:
10.1371/journal.ppat.1011359.s020
DOI:
10.1371/journal.ppat.1011359.s021
DOI:
10.1371/journal.ppat.1011359.s022
DOI:
10.1371/journal.ppat.1011359.s023
DOI:
10.1371/journal.ppat.1011359.s024
DOI:
10.1371/journal.ppat.1011359.s025
DOI:
10.1371/journal.ppat.1011359.s026
DOI:
10.1371/journal.ppat.1011359.s027
DOI:
10.1371/journal.ppat.1011359.s028
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2023
detail.hit.zdb_id:
2205412-1
Permalink